KromaTiD, Inc. Announces the Appointment of David Brunel to its Board of Directors
Retrieved on:
Wednesday, December 18, 2019
LONGMONT, Colo., Dec. 18, 2019 /PRNewswire/ --KromaTiD, Inc. today announced the appointment of David Brunel to its Board of Directors.
Key Points:
- LONGMONT, Colo., Dec. 18, 2019 /PRNewswire/ --KromaTiD, Inc. today announced the appointment of David Brunel to its Board of Directors.
- Mr. Brunel joins KromaTiD's Board with 19 years of experience in molecular diagnostics and over 20 years of experience in enterprise software.
- Mr. Brunel currently serves as Chief Executive Officer and Director at Biodesix, a company that develops and commercializes non-invasive blood-based molecular diagnostic tests for oncology.
- Effective January 1st, 2020, Mr. Brunel will transition from CEO to Chairman of Biodesix.